Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial

Area of Science:

• Cardiology
• Interventional Cardiology
• Diabetes Mellitus

Background:

• Diabetic women face higher risks of death and myocardial infarction (MI) post-percutaneous coronary intervention (PCI).
• Limited data exist on outcomes for diabetic women undergoing PCI in the current era.
• Current PCI strategies involve stents and glycoprotein IIb/IIIa inhibitors like abciximab.

Purpose of the Study:

• To evaluate the outcomes of diabetic women undergoing PCI using current techniques.
• To assess morbidity and mortality in diabetic women treated with stenting and abciximab.

Main Methods:

• Analysis of the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) database.
• Comparison of outcomes in diabetic women receiving stent-placebo, stent-abciximab, or balloon-abciximab.
• Assessment of 30-day, 6-month, and 1-year endpoints including death, MI, and target vessel revascularization (TVR).

Main Results:

• No significant mortality differences were observed at 30 days and 6 months across treatment groups.
• The primary endpoint (1-year death, MI, or TVR) was significantly reduced with stent-abciximab (13.3%) compared to stent-placebo (34.5%) and balloon-abciximab (28.9%).
• One-year TVR rates were substantially lower with stent-abciximab (4.5%) versus stent-placebo (21.1%) and balloon-abciximab (26.7%).

Conclusions:

• The combination of stenting and abciximab therapy significantly reduces 1-year rates of death, MI, or TVR in diabetic women.
• This combined approach represents an improvement over stent-placebo or balloon-abciximab therapies for this patient population.